TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International 7-Week, Double-Blind, Placebo-Controlled, 2-Parallel Group Study to Assess the Efficacy of Dianicline 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers
Brief Summary: The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotine withdrawal symptoms and the safety of dianicline.


Options:
A: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
C: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
D: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International 7-Week, Double-Blind, Placebo-Controlled, 2-Parallel Group Study to Assess the Efficacy of Dianicline 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers
Brief Summary: The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotine withdrawal symptoms and the safety of dianicline.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
D: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International 7-Week, Double-Blind, Placebo-Controlled, 2-Parallel Group Study to Assess the Efficacy of Dianicline 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers
Brief Summary: The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotine withdrawal symptoms and the safety of dianicline.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion (Wellbutrin) | Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bupropion | Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International 7-Week, Double-Blind, Placebo-Controlled, 2-Parallel Group Study to Assess the Efficacy of Dianicline 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers
Brief Summary: The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotine withdrawal symptoms and the safety of dianicline.


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 plus open label Nicotine replacement | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo plus open label Nicotine Replacement | Intervention Type: DRUG; Name: EVT 302; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: EVT 302 plus open label Nicotine replacement; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo plus open label Nicotine Replacement; Assigned to Arm(s): 4
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
D: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International 7-Week, Double-Blind, Placebo-Controlled, 2-Parallel Group Study to Assess the Efficacy of Dianicline 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers
Brief Summary: The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotine withdrawal symptoms and the safety of dianicline.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nasal Spray Nicotine Substitute (Experimental) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nasal Spray Nicotine Substitute (ad libitum) | Intervention Type: DRUG; Name: Nasal Spray Nicotine Substitute (Experimental); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nasal Spray Nicotine Substitute (ad libitum); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International 7-Week, Double-Blind, Placebo-Controlled, 2-Parallel Group Study to Assess the Efficacy of Dianicline 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers
Brief Summary: The primary objective is to demonstrate the efficacy of dianicline as an aid to smoking cessation in cigarette smokers. The main secondary objectives are: to assess the craving for cigarettes, nicotine withdrawal symptoms and the safety of dianicline.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered continuing professional development | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention arm | Intervention Type: BEHAVIORAL; Name: Internet-delivered continuing professional development; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: No intervention arm; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A
D: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Calcium and Vitamin D on Bone Loss From the Hip
Brief Summary: The primary aim of this study is to determine the effects of supplementation with both calcium and vitamin D on changes in bone density of the hip in men and women age 65 and older.


Options:
A: Arm Label: 90 Hz whole-body vibration; Type: EXPERIMENTAL; Interventions: Device: Juvent 1000 Dynamic Motion Therapy (DMT) Platform | Arm Label: 30 Hz whole-body vibration; Type: EXPERIMENTAL; Interventions: Device: Juvent 1000 Dynamic Motion Therapy (DMT) Platform | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Juvent 1000 Dynamic Motion Therapy (DMT) Platform; Assigned to Arm(s): 90 Hz whole-body vibration | Intervention Type: DEVICE; Name: Juvent 1000 Dynamic Motion Therapy (DMT) Platform; Assigned to Arm(s): 30 Hz whole-body vibration
B: Intervention Type: DRUG; Name: Calcium 500 mg/day and vitamin D 700 IU/day; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cure | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cure; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: OJ fortified with Ca and VitD; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Orange Juice fortified with Calcium and Vitamin D, Behavioral: Nutritional Counseling | Arm Label: OJ without VitD and Ca; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Orange juice without Ca or VitD, Behavioral: Nutritional Counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Orange Juice fortified with Calcium and Vitamin D; Assigned to Arm(s): OJ fortified with Ca and VitD | Intervention Type: DIETARY_SUPPLEMENT; Name: Orange juice without Ca or VitD; Assigned to Arm(s): OJ without VitD and Ca | Intervention Type: BEHAVIORAL; Name: Nutritional Counseling; Assigned to Arm(s): OJ fortified with Ca and VitD, OJ without VitD and Ca

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of [S,S]-Reboxetine Administered Once Daily in Patients With Fibromyalgia
Brief Summary: The purpose of this study is to assess the safety and effectiveness of \[S,S\]-Reboxetine in patients with fibromyalgia.


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
B: Arm Label: Amiloride; Type: EXPERIMENTAL; Interventions: Drug: Amiloride | Arm Label: Riluzole; Type: EXPERIMENTAL; Interventions: Drug: Riluzole | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Amiloride; Assigned to Arm(s): Amiloride | Intervention Type: DRUG; Name: Riluzole; Assigned to Arm(s): Riluzole | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo (for Duloxetine); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Duloxetine) | Arm Label: Remifentanil; Type: EXPERIMENTAL; Interventions: Drug: Remifentanil | Arm Label: Placebo (for Remifentanil); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Remifentanil) | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Remifentanil; Assigned to Arm(s): Remifentanil | Intervention Type: DRUG; Name: Placebo (for Remifentanil); Assigned to Arm(s): Placebo (for Remifentanil) | Intervention Type: DRUG; Name: Placebo (for Duloxetine); Assigned to Arm(s): Placebo (for Duloxetine)
D: Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Adult Caries Study
Brief Summary: Adult tooth decay is an infectious disease that afflicts the majority of Americans aged 55 and older and is the most common chronic disease at midlife with an ever growing economic toll. Despite the fact that specific bacteria cause tooth decay, no FDA-approved anti-microbial treatment for decay is available to the American dental professional. The Prevention of Adult Caries Study (PACS) is a study designed to evaluate the efficacy of a topical, temporary, 10% w/v chlorhexidine dental coating in reducing new decay in adult dental patients at risk for decay.


Options:
A: Arm Label: Placebo Dental Coating; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Active Dental Coating; Type: ACTIVE_COMPARATOR; Interventions: Drug: 10% w/v chlorhexidine acetate coating FDA IND #45466 | Intervention Type: DRUG; Name: 10% w/v chlorhexidine acetate coating FDA IND #45466; Assigned to Arm(s): Active Dental Coating | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Dental Coating
B: Arm Label: Training course for practice nurses in autonomy support; Type: EXPERIMENTAL; Interventions: Behavioral: Training course for practice nurses in autonomy support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training course for practice nurses in autonomy support; Assigned to Arm(s): Training course for practice nurses in autonomy support
C: Arm Label: CRM training of surgical teams; Type: N/A; Interventions: Other: Diffusion of a surgical safety checklist | Arm Label: No CRM training of surgical teams; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: Diffusion of a surgical safety checklist; Assigned to Arm(s): CRM training of surgical teams
D: Arm Label: Implementation intervention; Type: EXPERIMENTAL; Interventions: Other: Implementation intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation intervention; Assigned to Arm(s): Implementation intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients
Brief Summary: The purpose of this research is to study whether a multidisciplinary education in Diabetes and intervention for cardiac risk reduction in a group setting to modify patient behavior and adjust medications can achieve diabetes guideline goals for glycemia, blood pressure and lipid control.


Options:
A: Arm Label: MEDIC; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling and peer support, Behavioral: Interactive Education, Behavioral: Role modeling, Procedure: Pharmacologic case management | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling and peer support; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Interactive Education; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Role modeling; Assigned to Arm(s): MEDIC | Intervention Type: PROCEDURE; Name: Pharmacologic case management; Assigned to Arm(s): MEDIC
B: Arm Label: online mutual management; Type: EXPERIMENTAL; Interventions: Device: Welltang App | Arm Label: online self-management; Type: EXPERIMENTAL; Interventions: Device: Welltang App | Arm Label: hospital regular management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Welltang App; Assigned to Arm(s): online mutual management, online self-management
C: Arm Label: Geriatric diabetes team intervention group; Type: EXPERIMENTAL; Interventions: Other: Intervention for age specific barriers to self care | Arm Label: Attention Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Intervention for age specific barriers to self care; Assigned to Arm(s): Geriatric diabetes team intervention group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients
Brief Summary: The purpose of this research is to study whether a multidisciplinary education in Diabetes and intervention for cardiac risk reduction in a group setting to modify patient behavior and adjust medications can achieve diabetes guideline goals for glycemia, blood pressure and lipid control.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Enhanced pharmacist care; Type: EXPERIMENTAL; Interventions: Other: Enhanced pharmacist care | Intervention Type: OTHER; Name: Enhanced pharmacist care; Assigned to Arm(s): Enhanced pharmacist care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife
C: Arm Label: MEDIC; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling and peer support, Behavioral: Interactive Education, Behavioral: Role modeling, Procedure: Pharmacologic case management | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling and peer support; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Interactive Education; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Role modeling; Assigned to Arm(s): MEDIC | Intervention Type: PROCEDURE; Name: Pharmacologic case management; Assigned to Arm(s): MEDIC
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Other: High Intensity Intervention, Other: All- 6 month pharmacist intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low Intensity Intervention, Other: All- 6 month pharmacist intervention | Intervention Type: OTHER; Name: High Intensity Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Low Intensity Intervention; Assigned to Arm(s): Arm 2 | Intervention Type: OTHER; Name: All- 6 month pharmacist intervention; Assigned to Arm(s): Arm 1, Arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia
Brief Summary: The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in patients with symptomatic left ventricular systolic dysfunction and anemia.


Options:
A: Arm Label: CERA Treatment Once Monthly; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa Once Biweekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa Once Biweekly | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): CERA Treatment Once Monthly
B: Arm Label: Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: QM; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Q2W, QM
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
D: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D